Table 4.  Cardiovascular and respiratory adverse reactions observed per number of treatments.
Adverse reaction  Studies  Total number of treatments  Adverse reactions observed, n (%)  (min%–max%) †
Cardiac
   Hypotension ‡  [ 40, 51, 68]  323  10 (3)  (2–14) [ 68] - [ 40]
   Hypertension ‡  [ 25, 51, 68]  425  60 (14)  (3–21) [ 25] - [ 68]
   Bradycardia (mild and severe) ‡  [ 51]  54  4 (7)
   Decrease in heartrate ‡  [ 39]  32  30 (94)
   Tachycardia ‡  [ 51]  54  4 (7)
   Cardiac event, unspecified ‡  [ 74]  1269  35 (3)
   Chest discomfort/tightness ‡  [ 25, 68, 74]  1640  83 (5)  (0–6) [ 68] - [ 74]
Respiratory
   Dyspnea  [ 25, 68]  371  3 (1)  (0–2) [ 68] - [ 25]
   Shortness of breath ‡  [ 74]  1269  40 (3)
†Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.
‡ DMSO was administered intravenously.